Amylyx Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Amylyx Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AMLX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001658551
- EIN
- 46-4600503
Board of directors
-
Bernhardt G. Zeiher · DirectorSince 2024
-
Daphne Quimi · DirectorSince 2023
-
George M. Milne Jr. · DirectorSince 2023
-
Joshua B. Cohen · Director · Co-Chief Executive OfficerSince 2023
-
Justin B. Klee · Director · Co-Chief Executive OfficerSince 2023
-
Karen Firestone · DirectorSince 2023
-
Paul R. Fonteyne · DirectorSince 2023
Chief executives
Justin B. Klee
· Co-Chief Executive Officer
Dates unknown
Joshua B. Cohen
· Co-Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.5%
-
94.8%
Board connections
4 of this board's directors also sit on 5 other boards.
- via Bernhardt G. Zeiher
- via Paul R. Fonteyne
- via George M. Milne Jr.
- via Daphne Quimi
- via Bernhardt G. Zeiher
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $152,183
- 2 purchases by 1 insider
- Sold, last 12 months
- $10,623,185
- 37 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 10, 2026 | Justin B. Klee Director, Officer (Co-Chief Executive Officer) | Open-market sale | −29,025 | $32.13 | $932,553 |
| Sep 10, 2026 | Joshua B. Cohen Director, Officer (Co-Chief Executive Officer) | Open-market sale | −29,545 | $32.16 | $950,040 |
| Sep 10, 2026 | Mazzariello Gina Officer (Chief Legal Officer) | Open-market sale | −9,525 | $32.46 | $309,140 |
| Sep 10, 2026 | FRATES JAMES M Officer (Chief Financial Officer) | Open-market sale | −9,768 | $32.27 | $315,195 |
| Sep 10, 2026 | Camille L. Bedrosian Officer (Chief Medical Officer) | Open-market sale | −7,947 | $32.21 | $256,004 |
| Sep 10, 2026 | Justin B. Klee Director, Officer (Co-Chief Executive Officer) | Open-market sale | −1,439 | $33.16 | $47,710 |
| Sep 10, 2026 | Joshua B. Cohen Director, Officer (Co-Chief Executive Officer) | Open-market sale | −919 | $33.15 | $30,464 |
| Sep 10, 2026 | Mazzariello Gina Officer (Chief Legal Officer) | Open-market sale | −11 | $33.34 | $367 |
| Sep 10, 2026 | FRATES JAMES M Officer (Chief Financial Officer) | Open-market sale | −1,042 | $33.23 | $34,626 |
| Sep 10, 2026 | Camille L. Bedrosian Officer (Chief Medical Officer) | Open-market sale | −2,081 | $33.09 | $68,864 |
| Aug 31, 2026 | Karen Firestone Director | Option exercise | +25,000 | $1.76 | $44,000 |
| Aug 31, 2026 | Karen Firestone Director | Option exercise | +25,000 | $5.05 | $126,250 |
| Aug 18, 2026 | Joshua B. Cohen Director, Officer (Co-Chief Executive Officer) | Grant or award | +60,039 | — | — |
| Aug 18, 2026 | Camille L. Bedrosian Officer (Chief Medical Officer) | Grant or award | +22,807 | — | — |
| Aug 18, 2026 | Mazzariello Gina Officer (Chief Legal Officer) | Grant or award | +21,284 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.